☆ 4.8 Article

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

CANCER RESEARCH (2018)

Get Full Text
Add to Collection

Journal

CANCER RESEARCH
Volume 78, Issue 4 Supplement, Pages OT1-01-04-OT1-01-04

Publisher

American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.sabcs17-ot1-01-04

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.